Table 3.

Multivariate analysis

CharacteristicOSRFSDOR
HR95% CIP valueHR95% CIP valueHR95% CIP value
CAR T product: brexu-cel vs tisa-cel 0.71 0.18-2.75 .62 1.01 0.40-2.52 .98 0.85 0.26-2.74 .78 
Age, >21 vs ≤21 years 1.08 0.36-3.24 .90 1.59 0.68-3.72 .29 1.36 0.46-4.01 .57 
ALL subtype, Ph– vs Ph+ or Ph-like 1.48 0.46-4.81 .51 0.79 0.34-1.80 .57 0.50 0.19-1.32 .16 
Marrow disease before CAR T          
MRD− or MRD+ vs ≥5% blasts 0.23 0.06-0.86 .03 0.47 0.20-1.10 .08 0.79 0.29-2.15 .64 
Therapy before CAR T          
Allogeneic HCT, yes vs no 0.54 0.20-2.33 .38 0.47 0.17-1.30 .15 0.43 0.12-1.53 .20 
Blinatumomab, yes vs no 0.23 0.05-1.17 .08 0.33 0.11-1.02 .05 0.42 0.10-1.75 .23 
Inotuzumab, yes vs no 6.32 1.48-27.0 .01 3.65 1.41-9.46 .008 2.17 0.66-7.18 .21 
CharacteristicOSRFSDOR
HR95% CIP valueHR95% CIP valueHR95% CIP value
CAR T product: brexu-cel vs tisa-cel 0.71 0.18-2.75 .62 1.01 0.40-2.52 .98 0.85 0.26-2.74 .78 
Age, >21 vs ≤21 years 1.08 0.36-3.24 .90 1.59 0.68-3.72 .29 1.36 0.46-4.01 .57 
ALL subtype, Ph– vs Ph+ or Ph-like 1.48 0.46-4.81 .51 0.79 0.34-1.80 .57 0.50 0.19-1.32 .16 
Marrow disease before CAR T          
MRD− or MRD+ vs ≥5% blasts 0.23 0.06-0.86 .03 0.47 0.20-1.10 .08 0.79 0.29-2.15 .64 
Therapy before CAR T          
Allogeneic HCT, yes vs no 0.54 0.20-2.33 .38 0.47 0.17-1.30 .15 0.43 0.12-1.53 .20 
Blinatumomab, yes vs no 0.23 0.05-1.17 .08 0.33 0.11-1.02 .05 0.42 0.10-1.75 .23 
Inotuzumab, yes vs no 6.32 1.48-27.0 .01 3.65 1.41-9.46 .008 2.17 0.66-7.18 .21 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal